Melissa Morales1, Linda P Spear. 1. Department of Physiology & Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA, mmorales@wakehealth.edu.
Abstract
RATIONALE: NMDA antagonists consistently produce social inhibition in adult animals, although effects of these manipulations on social behavior of adolescents are relatively unknown. OBJECTIVES: The aim of this study was to assess potential age differences in the socially inhibitory effects of the non-competitive NMDA antagonist, MK-801, as well as NR2 subunit selective effects, given the regional and developmental differences that exist for the NR2 subunit during ontogeny. METHODS: In separate experiments, adolescent and adult male Sprague-Dawley rats were treated acutely with MK-801 (0, 0.05, 0.1, 0.2 mg/kg, i.p.), the NR2A antagonist, PEAQX (2.5, 5, 10, 20 mg/kg, s.c.), or the NR2B antagonist, ifenprodil (1.5, 3, 6, 12 mg/kg, i.p.), 10 min prior to a social interaction test. RESULTS: Adolescents required higher doses of MK-801 (0.1 and 0.2 mg/kg) to induce social suppression, whereas adults demonstrated reductions in social activity after all doses. Likewise, adolescents required higher doses of ifenprodil (6 and 12 mg/kg) to produce social inhibitory effects relative to adults (all doses). In contrast, adults were less sensitive to PEAQX than adolescents, with adults showing social inhibition after 20 mg/kg whereas adolescents showed this effect following 10 and 20 mg/kg. Although locomotor activity was generally reduced at both ages by all drugs tested, ANCOVAs using locomotor activity as a covariate revealed similar patterns of social inhibitory effects. CONCLUSIONS: Adolescents are less sensitive than adults to the disruption of social behavior by NMDA and NR2B-selective receptor antagonism, but not by an NR2A antagonist-age differences that may be related to different subunit expression patterns during development.
RATIONALE: NMDA antagonists consistently produce social inhibition in adult animals, although effects of these manipulations on social behavior of adolescents are relatively unknown. OBJECTIVES: The aim of this study was to assess potential age differences in the socially inhibitory effects of the non-competitive NMDA antagonist, MK-801, as well as NR2 subunit selective effects, given the regional and developmental differences that exist for the NR2 subunit during ontogeny. METHODS: In separate experiments, adolescent and adult male Sprague-Dawley rats were treated acutely with MK-801 (0, 0.05, 0.1, 0.2 mg/kg, i.p.), the NR2A antagonist, PEAQX (2.5, 5, 10, 20 mg/kg, s.c.), or the NR2B antagonist, ifenprodil (1.5, 3, 6, 12 mg/kg, i.p.), 10 min prior to a social interaction test. RESULTS: Adolescents required higher doses of MK-801 (0.1 and 0.2 mg/kg) to induce social suppression, whereas adults demonstrated reductions in social activity after all doses. Likewise, adolescents required higher doses of ifenprodil (6 and 12 mg/kg) to produce social inhibitory effects relative to adults (all doses). In contrast, adults were less sensitive to PEAQX than adolescents, with adults showing social inhibition after 20 mg/kg whereas adolescents showed this effect following 10 and 20 mg/kg. Although locomotor activity was generally reduced at both ages by all drugs tested, ANCOVAs using locomotor activity as a covariate revealed similar patterns of social inhibitory effects. CONCLUSIONS: Adolescents are less sensitive than adults to the disruption of social behavior by NMDA and NR2B-selective receptor antagonism, but not by an NR2A antagonist-age differences that may be related to different subunit expression patterns during development.
Authors: Julia J Turnock-Jones; Carol A Jennings; Melanie J Robbins; Jane E Cluderay; Jackie Cilia; Juliet L Reid; Adam Taylor; Declan N C Jones; Piers C Emson; Eric Southam Journal: Synapse Date: 2009-10 Impact factor: 2.562
Authors: Kathryn D Fischer; Alex C W Houston; Rajeev I Desai; Michelle R Doyle; Jack Bergman; Maha Mian; Rebekah Mannix; David L Sulzer; Se Joon Choi; Eugene V Mosharov; Nathaniel W Hodgson; Anita Bechtholt; Klaus A Miczek; Paul A Rosenberg Journal: Psychopharmacology (Berl) Date: 2018-02-22 Impact factor: 4.530
Authors: Lara S Hwa; Anna J Nathanson; Akiko Shimamoto; Jillian K Tayeh; Allison R Wilens; Elizabeth N Holly; Emily L Newman; Joseph F DeBold; Klaus A Miczek Journal: Psychopharmacology (Berl) Date: 2015-04-22 Impact factor: 4.530
Authors: Brian L Teng; Viktoriya D Nikolova; Natallia V Riddick; Kara L Agster; James J Crowley; Lorinda K Baker; Beverly H Koller; Cort A Pedersen; Michael B Jarstfer; Sheryl S Moy Journal: Neuropharmacology Date: 2015-12-31 Impact factor: 5.250
Authors: Sarah L Ferri; Ashley A Pallathra; Hyong Kim; Holly C Dow; Praachi Raje; Mary McMullen; Warren B Bilker; Steven J Siegel; Ted Abel; Edward S Brodkin Journal: Genes Brain Behav Date: 2019-12-12 Impact factor: 3.449
Authors: Clark W Bird; Daniel Barto; Christy M Magcalas; Carlos I Rodriguez; Tia Donaldson; Suzy Davies; Daniel D Savage; Derek A Hamilton Journal: Behav Brain Res Date: 2016-11-22 Impact factor: 3.332